Functional changes, increased apoptosis, and diminished nuclear factor-κB activity of myeloid dendritic cells during chronic hepatitis C infection

Human Immunology

Volumn 71, Issue 8, 2010, Pages 751-762

  Zhao, Li ^a   Shields, Justin ^a   Tyrrell, D Lorne ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Antigen presentation; Chronic hepatitis C; Immune tolerance; Immunology; Myeloid dendritic cells; NF B

Indexed keywords

CD86 ANTIGEN; HLA DR ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ADULT; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CELL FUNCTION; CELLULAR IMMUNODEFICIENCY; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOCYTOSIS; FEMALE; HEPATITIS C; HUMAN; HUMAN CELL; MALE; MYELOID DENDRITIC CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ANTIGENS, CD86; APOPTOSIS; BLOTTING, WESTERN; CELLS, CULTURED; DENDRITIC CELLS; FEMALE; FLOW CYTOMETRY; HEPATITIS C, CHRONIC; HLA-DR ANTIGENS; HUMANS; I-KAPPA B PROTEINS; IN SITU NICK-END LABELING; MALE; MICROSCOPY, CONFOCAL; MIDDLE AGED; MYELOID CELLS; NF-KAPPA B; T-LYMPHOCYTES;

EID: 77954757723     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2010.05.006     Document Type: Article

References (42)

1. Banchereau J., Briere F., Caux C., Davoust J., Lebecque S., Liu Y.J., et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000, 18:767-811.
2. Hart D.N. Dendritic cells: Unique leukocyte populations which control the primary immune response. Blood 1997, 90:3245-3287.
3. Chen M., Wang Y.H., Wang Y., Huang L., Sandoval H., Liu Y.J., Wang J. Dendritic cell apoptosis in the maintenance of immune tolerance. Science 2006, 311:1160-1164.
4. Mellman I., Steinman R.M. Dendritic cells: Specialized and regulated antigen processing machines. Cell 2001, 106:255-258.
5. Chisari F.V. Unscrambling hepatitis C virus-host interactions. Nature 2005, 436:930-932.
6. Brown R.S., Gaglio P.J. Scope of worldwide hepatitis C problem. Liver Transplant 2003, 9:S10-S13.
7. De Francesco R., Migliaccio G. Challenges and successes in developing new therapies for hepatitis C. Nature 2005, 436:953-960.
8. Alter M.J., Margolis H.S., Krawczynski K., Judson F.N., Mares A., Alexander W.J., et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med 1992, 327:1899-1905.
9. Thimme R., Bukh J., Spangenberg H.C., Wieland S., Pemberton J., Steiger C., et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci U S A 2002, 99:15661-15668.
10. Shoukry N.H., Cawthon A.G., Walker C.M. Cell-mediated immunity and the outcome of hepatitis C virus infection. Annu Rev Microbiol 2004, 58:391-424.
11. + T-cell response with HCV-elimination. J Hepatol 2003, 39:397-404.
12. Urbani S., Amadei B., Fisicaro P., Tola D., Orlandini A., Sacchelli L., et al. Outcome of acute hepatitis C is related to virus-specific CD4 function and maturation of antiviral memory CD8 responses. J Hepatol 2006, 44:126-139.
13. Bowen D.G., Walker C.M. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 2005, 436:946-952.
14. Meyer-Olson D., Shoukry N.H., Brady K.W., Kim H., Olson D.P., Hartman K., et al. Limited T-cell receptor diversity of HCV-specific T-cell responses is associated with CTL escape. J Exp Med 2004, 200:307-319.
15. Steinman R.M. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991, 9:271-296.
16. Perrin-Cocon L., Agaugue S., Diaz O., Vanbervliet B., Dollet S., Guironnet-Paquet A., et al. Th1 disabled function in response to TLR4 stimulation of monocyte-derived DC from patients chronically-infected by hepatitis C virus. PLoS ONE 2008, 3:e2260.
17. Saito K., Ait-Goughoulte M., Truscott S.M., Meyer K., Blazevic A., Abate G., et al. Hepatitis C virus inhibits cell surface expression of HLA-DR, prevents dendritic cell maturation, and induces interleukin-10 production. J Virol 2008, 82:3320-3328.
18. Kanto T., Inoue M., Miyazaki M., Itose I., Miyatake H., Sakakibara M., et al. Impaired function of dendritic cells circulating in patients infected with hepatitis C virus who have persistently normal alanine aminotransferase levels. Intervirology 2006, 49:58-63.
19. Szabo G., Dolganiuc A. Subversion of plasmacytoid and myeloid dendritic cell functions in chronic HCV infection. Immunobiology 2005, 210:237-247.
20. Averill L., Lee W.M., Karandikar N.J. Differential dysfunction in dendritic cell subsets during chronic HCV infection. Clin Immunol 2007, 123:40-49.
21. Larsson M., Babcock E., Grakoui A., Shoukry N., Lauer G., Rice C., et al. Lack of phenotypic and functional impairment in dendritic cells from chimpanzees chronically infected with hepatitis C virus. J Virol 2004, 78:6151-6161.
22. Longman R.S., Talal A.H., Jacobson I.M., Rice C.M., Albert M.L. Normal functional capacity in circulating myeloid and plasmacytoid dendritic cells in patients with chronic hepatitis C. J Infect Dis 2005, 192:497-503.
23. Piccioli D., Tavarini S., Nuti S., Colombatto P., Brunetto M., Bonino F., et al. Comparable functions of plasmacytoid and monocyte-derived dendritic cells in chronic hepatitis C patients and healthy donors. J Hepatol 2005, 42:61-67.
24. Barnes E., Salio M., Cerundolo V., Francesco L., Pardoll D., Klenerman P., Cox A. Monocyte derived dendritic cells retain their functional capacity in patients following infection with hepatitis C virus. J Viral Hepat 2008, 15:219-228.
25. Dzionek A., Fuchs A., Schmidt P., Cremer S., Zysk M., Miltenyi S., et al. BDCA-2, BDCA-3, and BDCA-4: Three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol 2000, 165:6037-6046.
26. Haase C., Ejrnaes M., Juedes A.E., Wolfe T., Markholst H., von Herrath M.G. Immunomodulatory dendritic cells require autologous serum to circumvent nonspecific immunosuppressive activity in vivo. Blood 2005, 106:4225-4233.
27. Li W., Krishnadas D.K., Li J., Tyrrell D.L., Agrawal B. Induction of primary human T-cell responses against hepatitis C virus-derived antigens NS3 or core by autologous dendritic cells expressing hepatitis C virus antigens: Potential for vaccine and immunotherapy. J Immunol 2006, 176:6065-6075.
28. Natarajan K., Singh S., Burke T.R., Grunberger D., Aggarwal B.B. Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-kappa B. Proc Natl Acad Sci U S A 1996, 93:9090-9095.
29. Santini S.M., Lapenta C., Logozzi M., Parlato S., Spada M., Di Pucchio T., Belardelli F. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J Exp Med 2000, 191:1777-1788.
30. Tzachanis D., Berezovskaya A., Nadler L.M., Boussiotis V.A. Blockade of B7/CD28 in mixed lymphocyte reaction cultures results in the generation of alternatively activated macrophages, which suppress T-cell responses. Blood 2002, 99:1465-1473.
31. Revy P., Sospedra M., Barbour B., Trautmann A. Functional antigen-independent synapses formed between T cells and dendritic cells. Nat Immunol 2001, 2:925-931.
32. Lee J.I., Burckart G.J. Nuclear factor kappa B: Important transcription factor and therapeutic target. J Clin Pharmacol 1998, 38:981-993.
33. tKarlsson A., Nygren E., Karlsson J., Nordstrom I., Dahlgren C., Eriksson K. Ability of monocyte-derived dendritic cells to secrete oxygen radicals in response to formyl peptide receptor family agonists compared to that of myeloid and plasmacytoid dendritic cells. Clin Vaccine Immunol 2007, 14:328-330.
34. Holling T.M., Schooten E., van Den Elsen P.J. Function and regulation of MHC class II molecules in T-lymphocytes: Of mice and men. Hum Immunol 2004, 65:282-290.
35. Goodkin M.L., Ting A.T., Blaho J.A. NF-kappaB is required for apoptosis prevention during herpes simplex virus type 1 infection. J Virol 2003, 77:7261-7280.
36. Li Q., Verma I.M. NF-kappaB regulation in the immune system. Nat Rev Immunol 2002, 2:725-734.
37. Yoshimura S., Bondeson J., Foxwell B.M., Brennan F.M., Feldmann M. Effective antigen presentation by dendritic cells is NF-kappaB dependent: Coordinate regulation of MHC, co-stimulatory molecules and cytokines. Int Immunol 2001, 13:675-683.
38. Kriehuber E., Bauer W., Charbonnier A.S., Winter D., Amatschek S., Tamandl D., et al. Balance between NF-kappaB and JNK/AP-1 activity controls dendritic cell life and death. Blood 2005, 106:175-183.
39. Pham T.N., King D., Macparland S.A., McGrath J.S., Reddy S.B., Bursey F.R., Michalak T.I. Hepatitis C virus replicates in the same immune cell subsets in chronic hepatitis C and occult infection. Gastroenterology 2008, 134:812-822.
40. Siavoshian S., Abraham J.D., Thumann C., Kieny M.P., Schuster C. Hepatitis C virus core, NS3, NS5A, NS5B proteins induce apoptosis in mature dendritic cells. J Med Virol 2005, 75:402-411.
41. Goutagny N., Fatmi A., De Ledinghen V., Penin F., Couzigou P., Inchauspe G., Bain C. Evidence of viral replication in circulating dendritic cells during hepatitis C virus infection. J Infect Dis 2003, 187:1951-1958.
42. Shao S.W., Wu W.B., Bian Z.Q., Yu J.G., Zhao P., Zhao L.J., et al. Hepatitis C virus F protein inhibits cell apoptosis by activation of intracellular NF-kappaB pathway. Hepatol Res 2009, 39:282-289.